Zosuquidar (LY335979) 3HCl: P-glycoprotein Modulator for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent and selective inhibitor of P-glycoprotein (P-gp), a major ATP-dependent efflux pump implicated in multidrug resistance (MDR) in cancer (Sun et al., 2025). At low micromolar concentrations, Zosuquidar restores the sensitivity of leukemia and solid tumor cell lines to chemotherapeutics including vinblastine, doxorubicin, etoposide, and paclitaxel [DOI]. In vivo studies confirm enhanced antitumor activity and survival when Zosuquidar is combined with standard chemotherapy, with negligible impact on pharmacokinetics [DOI]. Clinical trials indicate effective P-gp inhibition and minimal toxicity in combination regimens for non-Hodgkin's lymphoma and advanced solid tumors [DOI]. APExBIO offers rigorously validated Zosuquidar (LY335979) 3HCl (SKU A3956) for MDR reversal research [product].

Biological Rationale

P-glycoprotein (P-gp, also known as ABCB1) is an ATP-dependent membrane efflux transporter broadly expressed in the liver, intestine, brain, and tumor cells (Sun et al., 2025). P-gp actively transports a diverse range of chemotherapeutic agents out of cancer cells, reducing their intracellular accumulation and efficacy. Overexpression of P-gp is a principal driver of multidrug resistance (MDR) in both hematologic and solid tumors. MDR is associated with poor therapeutic outcomes, disease progression, and treatment failure. Inhibition of P-gp is a validated strategy for restoring drug sensitivity in resistant cancer models. Pharmacokinetic studies reveal that the function and expression of P-gp are modulated by disease status and co-administered drugs, necessitating precise tools for its selective inhibition [DOI].

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar is a tricyclic compound that competitively inhibits the substrate-binding site of P-gp. It blocks the efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel. In vitro, Zosuquidar acts at low micromolar concentrations (typically 0.1–1 μM) to restore drug accumulation in P-gp-overexpressing cell lines. It does not significantly inhibit other transporters (e.g., MRP1, BCRP) at these concentrations, conferring high selectivity (Sun et al., 2025). In vivo, Zosuquidar enhances the cytotoxicity of chemotherapeutics in murine models of MDR leukemia and human tumor xenografts. Importantly, co-administration with cytotoxic drugs does not significantly alter their systemic pharmacokinetics or toxicity profiles [DOI].

Evidence & Benchmarks

• Zosuquidar at 0.5–1 μM restores vinblastine sensitivity by >90% in P-gp-overexpressing leukemia cell lines in vitro (Sun et al., 2025).
• In vivo, Zosuquidar (5 mg/kg, i.p.) combined with doxorubicin doubles median survival in murine MDR leukemia models, compared to chemotherapy alone (Sun et al., 2025).
• Clinical phase I/II trials show Zosuquidar (200 mg orally, q12h) plus CHOP chemotherapy achieves sustained P-gp inhibition and favorable safety in non-Hodgkin’s lymphoma (Sun et al., 2025).
• Pharmacokinetic interaction studies confirm that Zosuquidar does not significantly affect vinorelbine or doxorubicin plasma concentrations in patients (Sun et al., 2025).
• Validated as a benchmark P-gp inhibitor in translational oncology workflows (Concanavalin-A Review).

This article extends the mechanistic and translational context compared to prior summaries, such as "Zosuquidar (LY335979) 3HCl and the Future of Multidrug Resistance Reversal", by directly mapping quantitative benchmarks and clinical data. For practical workflow guidance, see "Optimizing MDR Assays with Zosuquidar (LY335979) 3HCl: Practical Guidance", which this article complements by focusing on evidence thresholds and selectivity boundaries.

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is used in preclinical and translational research to reverse MDR in acute myeloid leukemia (AML), non-Hodgkin’s lymphoma, and solid tumors. It is suitable for in vitro cytotoxicity assays, in vivo xenograft studies, and as a control in P-gp substrate validation. Zosuquidar does not significantly affect other ABC transporters at effective concentrations, minimizing off-target effects. It is soluble in DMSO and should be stored at -20°C (APExBIO). Solutions are not recommended for long-term storage due to potential degradation.

Common Pitfalls or Misconceptions

• Zosuquidar is not a pan-ABC transporter inhibitor: It is selective for P-gp and does not significantly inhibit MRP1 or BCRP at standard concentrations.
• Does not reverse resistance due to non-efflux mechanisms: Ineffective where MDR arises from altered drug targets, apoptosis pathways, or DNA repair.
• Not a substitute for cytotoxic drugs: Zosuquidar must be co-administered with chemotherapeutic agents to observe MDR reversal.
• Solutions are not stable long-term: Freshly prepare Zosuquidar solutions for each experiment to ensure activity.
• Clinical efficacy may be disease- and regimen-dependent: Optimal benefit observed in P-gp overexpressing cancers; not all tumors exhibit MDR via P-gp.

Workflow Integration & Parameters

Zosuquidar (LY335979) 3HCl (SKU A3956) from APExBIO is validated for MDR research workflows. For in vitro assays, typical concentrations are 0.1–2 μM in DMSO, added concurrently with chemotherapeutics. For in vivo studies, published protocols use 5 mg/kg i.p. or 200 mg oral doses, with timing matched to chemotherapy administration. Store powder at -20°C and avoid repeated freeze-thaw cycles. Use freshly prepared solutions. Refer to the A3956 kit for detailed handling guidelines. Enhanced reproducibility and sensitivity in P-gp-dependent assays have been independently verified (Practical Guidance). For troubleshooting, see scenario-driven Q&As in "Solving Multidrug Resistance: Zosuquidar (LY335979) 3HCl", which details common laboratory challenges.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a benchmark P-gp modulator for translational oncology and MDR research. It restores chemotherapeutic efficacy in P-gp-overexpressing models, is clinically validated, and is available with rigorous quality control from APExBIO. Ongoing studies are refining its roles in combinatorial regimens and as a reference standard for efflux pump inhibition. As new MDR mechanisms emerge, Zosuquidar remains a key tool for dissecting cancer drug resistance pathways. For ordering, protocols, and documentation, visit APExBIO’s Zosuquidar (LY335979) 3HCl.